Alkermes (ALKS) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alkermes (ALKS) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 57.1% versus a loss of 17.7%. Over five years, CORT leads with a +196.0% price change compared with +100.0% for ALKS. Alkermes is the larger company by market cap ($7.55 billion vs $6.96 billion), about 1.1 times the size, while Corcept Therapeutics is growing revenue faster (+12.8% vs -5.2%).
On valuation, Corcept Therapeutics trades at a lower forward P/E (12.8x vs 33.2x for Alkermes). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | CORT |
|---|---|---|
| Share price | $44.94 | $63.62 |
| Market cap | $7.55B | $6.96B |
| 1-day change | -2.69% | -2.09% |
| YTD return | +60.61% | +82.82% |
| 1-year return | +57.08% | -17.69% |
| 5-year return | +100.00% | +196.04% |
| P/E ratio (TTM) | — | 47.83 |
| Forward P/E | 33.21 | 12.77 |
| EPS (TTM) | $-0.01 | $1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $761.41M |
| Revenue growth (YoY) | -5.25% | +12.79% |
| Net income (latest FY) | $241.66M | $99.65M |
| Gross margin | 86.69% | 98.30% |
| Operating margin | 17.21% | 5.88% |
| Net margin | 16.37% | 13.09% |
| 52-week high | $55.67 | $126.38 |
| 52-week low | $27.00 | $28.66 |
| Distance from 52-week high | -19.27% | -49.66% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +28.48% | +124.14% |
| Average volume | 1.90M | 1.26M |
| Shares outstanding | 168.04M | 109.44M |
| Employees | 2,050 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALKS has outperformed CORT by 74.8 percentage points over the past year.
- Corcept Therapeutics grew revenue faster in its latest fiscal year (+12.79% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
ALKS vs CORT FAQ
Which is bigger, Alkermes or Corcept Therapeutics?
Alkermes (ALKS) is larger, with a market capitalization of $7.55B compared with $6.96B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, ALKS or CORT?
ALKS returned +57.08% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.